Submit Manuscript  

Article Details


CYP3A4 *1B Gene Polymorphism in Coronary Artery Disease Patients with Obesity Undergoing Statin Treatment

Author(s):

Elifcan Gezer, Mehtap Cevik, Cansu Selcan Akdeniz, Ismail Polat Canbolat, Selen Yurdakul, Murat Sunbul, Penbe Cagatay, Gokce Deliorman, Atila Karaalp, Cavlan Ciftci and Belgin Susleyici*   Pages 1 - 6 ( 6 )

Abstract:


Objective: Coronary artery disease (CAD) is the one of the leading cause of morbidity and mortality worldwide and statins are frequently prescribed in the treatment of CAD to help lower blood cholesterol levels. Since the main enzyme involved in the metabolism of statins is CYP3A4, we aimed to investigate the effect of CYP3A4 * 1B genotypes on plasma lipid profile in Turkish cardiovascular disease subject with and without obesity taking statin.

Materials and Methods: The study group consisted of 85 cardiovascular disease patients who were prescribed statins and had routine biochemical analysis data. Polymerase chain reaction followed by restriction fragment length polymorphism (PCR-RFLP) assay were performed for genotyping of CYP3A4 *1B (rs2740574) polymorphism.

Results: Genotype distribution of CYP3A4 *1B polymorphism was found for homozygous wild (AA) and homozygous polymorphic (GG) genotypes as 94.1% and 5.9% respectively. We did not detect patients with heterozygous genotype in our study group. We found that the mean LDL-c, TG and TC levels were higher in patients with CYP3A4 *1B GG compared to AA genotype. The frequency of CYP3A4 *1B GG genotype frequency (9.5%) was detected higher in the obese patients compared to the non-obese patients (7.7%) (χ2=0.037, p=0.85).

Conclusions: Our results demonstrate that CYP3A4 *1B homozygous polymorphic genotype distribution tend to be higher in obese patients compared to non- obese patients with cardiovascular disease which may point *1B allele to have a slight effect on serum lipids during statin therapy. Additional studies with higher samples are needed for evaluating the role of CYP3A4 *1B on lipids in patients under statin therapy.

Keywords:

cardiovascular disease, statins, CYP3A4, 290 A>G, serum lipids, obesity

Affiliation:

Marmara University, Faculty of Science and Letters, Department of Molecular Biology, Istanbul, Marmara University, Faculty of Science and Letters, Department of Molecular Biology, Istanbul, Demiroglu-Bilim University, Faculty of Medicine, Department of Cardiology, Istanbul, Demiroglu-Bilim University, Faculty of Medicine, Department of Cardiology, Istanbul, Demiroglu-Bilim University, Faculty of Medicine, Department of Cardiology, Istanbul, Marmara University, Faculty of Medicine, Department of Cardiology, Istanbul, Istanbul University - Cerrahpasa, Vocational School of Health Service, Department of Medical Services and Technics, Istanbul, Beykoz University, Faculty of Engineering and Architecture, Department of Software Engineering, Istanbul, Marmara University, Faculty of Medicine, Department of Medical Pharmacology, Istanbul, Demiroglu-Bilim University, Faculty of Medicine, Department of Cardiology, Istanbul, Marmara University, Faculty of Science and Letters, Department of Molecular Biology, Istanbul



Read Full-Text article